Tillotts Pharma outsources HR to Apodi

by JoelLane 10. June 2013 16:05

mark murphy Gastroenterology treatment specialist Tillotts Pharma UK has signed up Apodi to provide its HR and development service.

Jeremy Thorpe, Tillotts Pharma UK’s Country Manager, said: “Apodi came to us well regarded and are experienced in dealing with similar organisations to ourselves. We took the decision to work with Apodi as we are keen to benefit from the wider skill set that they could offer to help us help our staff.”

Mark Murphy (pictured), Apodi’s Business Unit Director for HR & Development services, commented: “As a highly experienced HR&D team with a strong heritage in the pharmaceutical and healthcare sectors, we have a wealth of experience and credibility in dealing with HR issues typical to the pharmaceutical industry.”

Tillotts Pharma UK, an affiliate of the Swiss-based Tillotts Pharma, specialises in developing, in/out licensing and marketing innovative drugs, diagnostics and medical devices in the field of gastroenterology.

Apodi is a leading provider of outsourcing solutions to pharmaceutical and healthcare companies, with a focus on the new NHS commercial environment. Its HR & Development unit helps clients to optimise workplace performance.

Tags: , , , , , , , ,

General

First cut is the deepest

by IainBate 24. May 2013 17:01

 

The birth of the new, deregulated NHS came only days before the death of the politician whose career made it possible. Pf looks back on the legacy of the Thatcher era for healthcare in the UK.

When Margaret Thatcher died on the 8th April, they were still removing the last shreds of bubble wrap from the new NHS structure. The blueprint of the Health and Social Care Act (2012) is a monument to Thatcherism. It transforms the NHS from a nationally owned, publicly funded healthcare system to one driven by competition and governed by business law – a system designed for rapid, continuous change under the influence of market forces.

The architect of these reforms, Andrew Lansley, is a politician very much in the Thatcher mould: autocratic, forceful, not worried about consensus. His statement that the Government’s ‘listening exercise’ was only necessary because the doctors had to have the reforms explained to them was straight out of the Iron Lady handbook.

In order to assess the impact of Thatcher’s legacy on healthcare, it’s essential to appreciate that NHS market reforms began on her watch. Even the relatively minor step of outsourcing hospital cleaning was casting a shadow over hospital care decades later.

And the fundamental reforms outlined in 1989 – the NHS internal market and the purchaser/provider split – laid the foundations of the market reforms that followed under the governments of Major, Blair, Brown and Cameron. As historian Charles Webster has observed, the 1980s and 1990s saw “continuous revolution” for the NHS.

It’s become a cliché of retrospectives on Thatcher to say that the Iron Lady ‘left the NHS alone’. It’s true that her government had other fish to fry, notably the onslaught on the manufacturing industries and their trade unions that culminated in the miners’ strike.

Thatcher noted in her memoirs that in most respects, the NHS provided “high quality care at reasonably modest unit cost” and commanded public “affection”. She was in no hurry to privatise it – but that did not mean she left it alone.

Iron rations

However, the Thatcher government’s first health policy initiative was one of deliberate inaction. The Black Report into health inequalities, published in 1980 after a failed Conservative attempt to block its publication, noted that health inequalities in the UK were linked to socio-economic factors such as income, housing and conditions of work. The Government rejected the report’s findings and recommendations.

The 1980s were not an easy decade for the NHS. Major developments in drug therapies and surgery increased healthcare expectations and costs, while a massive increase in unemployment accentuated public health needs. The main theme of Thatcher’s health policy was cost control, building on the public spending restraints of the Callaghan government. The phrase ‘death by a thousand cuts’ became endemic in health journalism.

Diabetes patient Richard Grimes recalls the austerity climate of the NHS at that time: “My memories of that clinic were peeling paint on the outside and a filled waiting room on the inside. The most bitter memory was the battle the British Diabetic Association had with the government over disposable needles. I was expected to inject twice a day with re-usable needles. These got blunt quickly, but I was expected to use them for months. As a result I developed scar tissue in my injection sites. Finally the Thatcher government relented and I got sharp needles.”

Two significant policies of the early Thatcher years increased the role of the private sector in healthcare. In 1980, NHS consultants’ contracts were changed to allow all to do private work with no detriment to their NHS income (previously those also doing private work were paid about 18% less). As a result, it became the norm for consultants to divide their time between the public and private sectors.

In 1983, the government legislated to make hospitals put their cleaning services out to competitive tender. This meant that the job of cleaning wards went to the lowest bidder – often to companies that used casual, untrained sta. supplied by job centres. The contrast between the high quality of surgical treatment and the dirtiness of wards became notorious. The level of hospital-acquired infections grew steadily, until in 2005 the Lancet noted that the UK had “one of the highest rates of MRSA in the world”.

Thatcher wanted to introduce more radical changes – such as a shift to an insurance based healthcare model, with ‘health stamps’ for the poor – but in a busy decade, her battles with trade unions and left-wing Labour councils took priority.

The great divide

The third Thatcher term saw a crisis of hospital capacity, provoking a review of the NHS that aimed to address its financial problems through competition. The 1989 White Paper Working for Patients gave rise to the NHS and Community Care Act (1990), engineered by the ambitious Health Secretary Kenneth Clarke within the Major government. It introduced two important reform policies.

The NHS internal market separated the functions of purchasers (health authorities) and providers (hospitals and other organisations). The latter competed for service contracts within a business framework. Hospitals became trusts: independent, self-managed bodies. By 1997 almost all NHS hospitals were trusts. One effect of this change was that administration costs doubled from 6% to 12% of the NHS budget.

GP fundholding was an attempt to develop a similar framework for primary care. Family doctors were encouraged to join a scheme whereby they received budgets to buy non-emergency care services from NHS providers, instead of relying on those purchased in bulk by their health authority.

Fundholding doctors were often able to obtain services more quickly than those outside the scheme. By 1997 about 50% of GPs were fundholders. The scheme cooled the professional relationship between primary and secondary care, and many patients saw it as a ‘two-tier’ healthcare model.

The internal market and GP fundholding can be seen as a dry run for the current NHS reforms, which embody the same principles but strengthen them by reshaping the health system around them.

Dragon’s Den

‘Save the NHS’ was a key slogan for Labour in the 1997 election: its campaign played on the unpopularity of the internal market and GP fundholding. Blair’s first Health Secretary, Frank Dobson, proudly announced the abolition of both policies. But as Peter Mandelson has said, New Labour’s programme was continuous with . atcherism – and soon, Dobson and his beard were forgotten and Alan Milburn was turning the NHS into a Dragon’s Den for private providers. Webster notes that Blair did far more than Thatcher to bring the private sector into the NHS.

Facing the challenges of growing demand and innovative therapies, especially in cancer and mental health care, Milburn’s NHS Plan (2000) ushered in a new world of NHS ‘modernisation’: Private Finance Initiatives, Practice Based Commissioning, Payment by Results, Foundation Trusts (which were self-funding), and the new mantra of NHS reform: ‘patient choice’.

Under Brown’s leadership, however, the Mid Staffordshire tragedy knocked the wheels off the reform agenda. Alan Johnson, the Health Secretary left to clear up after the worst ever failure in NHS care, slowed down the transition of acute trusts to Foundation Trust status. His successor, Andy Burnham, reacted to problems with Independent Sector Treatment Centres – who withheld their performance data as ‘commercially confidential’ – by stating the NHS to be the ‘preferred provider’ of elective surgery. With language like that, you’d think he was in the Labour Party.

Here comes the son

In opposition, Conservative activists published a policy book called Direct Democracy (2005). It claimed the NHS was “no longer relevant”, and proposed a system whereby patients were funded “either through the tax system or by way of universal insurance, to purchase health care from the provider of their choice” – with the poor having their contributions “supplemented or paid for by the state”. The authors included future Health Secretary Jeremy Hunt.

In its 2010 election manifesto, the Conservatives promised an end to the relentless NHS reforms of the previous government: it would inflict no major structural changes on the NHS. Once in power, with no sense of irony, Lansley introduced his reform programme as the first major NHS reform since 1948.

However, the Cameron government learned an important lesson from the Thatcher years. The Iron Lady’s confrontational style rallied supporters, but also gave opposition a clear point of attack.

In selling the NHS reforms to the public, Cameron kept repeating two points: the NHS budget would remain ring-fenced, and NHS services would remain free. We now know that the £20bn saved under the ‘Nicholson challenge’ is going straight back to the Treasury; and Malcolm Grant has warned us that after 2015, charges for NHS services are on the cards.

So, in bringing off a health policy revolution that Thatcher would have been proud of, Cameron utilised a spin technique that carried Blair’s fingerprints: Don’t show your hand.

 

Merck Serono and Quintiles team up for drug development

by JoelLane 17. May 2013 10:10

Tom Pike - Quintiles - Web Pharmaceutical giant Merck Serono and leading industry service provider Quintiles have formed a five-year clinical development partnership.

The unique collaboration aims to optimise productivity in the design and execution of clinical drug trials, speeding the development of new treatment options in Merck Serono’s core therapy areas: neurology, oncology and immunology.

Merck Serono will shape and lead the partnership’s drug development programme; Quintiles will direct the planning and conducting of clinical trials and contribute to ongoing trial design.

Quintiles will be the sole primary provider of Merck Serono’s outsourced drug development services. It will also participate in strategic decisions regarding the development of the pharma company’s portfolio.

The partnership reflects the pivotal role of contract research organisations and other service providers in the global pharmaceutical industry.

“By combining the strengths of Merck Serono and Quintiles, we are creating a new model in clinical development that will unlock the knowledge and insights of both companies,” said Annalisa Jenkins, Executive VP and Head of Global Development and Medical at Merck Serono.

“This is an innovative and unique collaboration that will help to translate the highest-quality science into efficiency and agility throughout our clinical trials, while enhancing our competitive position in an increasingly challenging environment of clinical drug development.”

Tom Pike (pictured), CEO of Quintiles, commented: “We view this as a key step forward not only for our two companies, but for the way the industry approaches the development of new therapies for the patients we ultimately serve.”

Merck Serono is the biopharmaceutical division of Merck, based in Darmstadt, Germany. Quintiles is the largest global provider of drug development and commercial outsourcing services to the pharmaceutical industry.

CBI says only privatisation can save the NHS

by JoelLane 24. September 2012 15:24

UFT_163498_0012 Only outsourcing to the private sector can save the NHS and other public services, according to the Confederation of British Industry (CBI).

A report commissioned by the CBI estimated that outsourcing of public services could save the Government £22.6bn a year by enabling adoption of more efficient business methods.

CBI Director General John Cridland said the report proved that for UK public services “business as usual is not an option”.

He criticised the coalition Government for failing to deliver on the policies of its 2011 white paper Open Public Services, which promised rapid privatisation.

The report, produced by economics consultancy Oxford Economics, analysed the impact of outsourcing on a range of discrete public services including hospital facilities management, cleaning and catering.

The consultancy noted that services run by private providers were on average 11% more efficient than those provided directly by the public sector.

If all public services were privatised, it concluded, £22.6bn a year could be saved – including £527m a year from hospital facilities management.

Cridland argued that the Government needed to overcome public sector “inertia” and open up all public service contracts to competitive tendering.

Ali Parsa, CEO of Circle Healthcare – now running Hinchingbrooke Hospital in Cambridgeshire – agreed with the report, adding: “Without greater competition it will be a race to the bottom with public services delivering less with less.”

Like the recent report from corporate finance consultant Catalyst predicting a tenfold increase in the NHS market for private health companies, the CBI report reflects the greatly increased private sector interest in NHS franchises.

ABPI partners with outsourcing specialist

by IainBate 15. August 2012 12:37

ABPI partners with outsourcing specialist - Pharamceutical Field The ABPI has appointed outsourcing specialists Apodi to support its human resources requirements.

The agreement is part of the Association’s modernisation agenda to move away from ‘in-house support’.

Stephen Whitehead, ABPI Chief Executive, said the trade association was “really pleased” with the decision to appoint Apodi and they are “really enjoying working with them”.

The HR and development unit at Apodi helps clients in building high performing organisations by optimising workplace performance.

“As a highly experienced HR and development team with a strong heritage in the pharmaceutical and healthcare sectors, we have a wealth of experience and credibility in dealing with HR issues typical to the Pharmaceutical industry,” said Mark Murphy, Apodi’s Business Unit Director for HR and Development services.

Tags: , , , , , , ,

News

India and China set to become global CMO centres

by JoelLane 16. May 2012 17:22

Pf industry news India and China are set to become the drug industry’s global hubs for Contract Manufacturing Organisations (CMOs).

The governments of both countries have changed their business and regulatory frameworks to encourage pharmaceutical outsourcing from other countries.

A new report from business intelligence source GBI Research says the global drug CMO market will grow steadily as Western pharma companies outsource their production to Asia.

The global drug CMO market is predicted to grow from $26bn in 2010 to $60bn in 2018, with outsourcing of biologics and generics being the main growth areas.

India and China in particular have benefited from the development of factories that meet global regulatory criteria for drug manufacturing.

In 2005, India’s Biotechnology Policy simplified procedures for regulatory clearance and granted exemptions from import duties and service taxes, while a new patent regime made it easier for pharmaceutical companies to protect their intellectual property rights in India.

China’s State Food and Drug Administration (SFDA) has stated contract drug manufacturing to be a long-term economic goal. The legal framework for contract manufacturing in China on behalf of countries outside China was introduced in 2001 and refined in 2003.

Pharma jobs increasing in Europe

by IainBate 9. May 2012 10:53

Pharma Industry News An increase in pharmaceutical jobs in Europe helped the total number of life sciences roles increase by 3.7% in the first three months of 2012, according to a report.

ZRG Partners’ Life Science Hiring Index found pharmaceutical jobs increased by 25% in the first quarter in the EMEA region, despite a reduction in sales and marketing and R&D positions.

Job growth in the global medical device industry also increased by 6.8% as roles in the Asia Pacific region jumped by 102% – mainly due to recruitment by Philips and Siemens.

But the report found that outsourcing and CRO positions fell by 5.7% after roles in North America were substantially cut and jobs remained flat in Asia Pacific.

Hiring activity in the Americas decreased by a tenth, however it still recorded its highest level in the past two years, research found.

The EMEA region reversed a trend in the past six months as overall positions increased by 18% with a rise in pharmaceutical and outsourcing roles; medical device positions remained flat.

Regulatory, clinical and quality positions made up more than a third (36%) of jobs in EMEA, followed by IT, finance and general administrative positions (31%). Research and development roles made up nearly a fifth (18%) of overall positions with sales and marketing jobs making up 11% and manufacturing accounting for just 4% of all roles.

Emerging markets in the Asia Pacific region again helped boost the global outlook as the amount of jobs also increased by 18%, despite outsourcing/CRO remaining flat and pharmaceutical jobs falling.

Despite the US already cutting 4,800 jobs this year, according to outplacement consulting firm Challenger Gray & Christmas, the Index found that the Americas still account for 51% of global life science roles, followed by EMEA (28%) and Asia Pacific (21%).

EMA and FDA to share manufacturing inspections

by JoelLane 13. December 2011 16:24

Pf industry news The European Medicines Agency (EMA) and the Food and Drug Administration (FDA) in the US will share manufacturing site inspections from January 2012.

The initiative is expected to free up resources for the regulators and reduce the burden of inspections on pharmaceutical manufacturers.

It will apply to inspections of manufacturing sites for human or veterinary medicines in the EU or the US, and will focus initially on sites with a history of good manufacturing practice.

The EMA and FDA currently carry out many inspections in each other’s territories, with much duplication of work.

A further factor is the trend for pharmaceutical companies in Europe and the US to outsource their manufacturing to China or India, making the process global rather than national.

According to the EMA, the changes will mostly affect post-authorisation rather than pre-authorisation inspections.

The initiative follows two pilot projects run by the EMA and FDA to trial the sharing of inspection data:

• An 18-month Good Clinical Practice initiative whereby the two regulatory bodies exchanged more than 250 documents relating to 54 medications.

• A two-year project to cover inspections for joint active pharmaceutical ingredients in the EU, the US and Australia. The participants exchanged nearly 100 inspection reports and nine joint inspections.

The EMA commented that the pilots had increased the shared knowledge of both agencies and identified a number of inspections that would be useful in more than one region.

Vention and ATEK form combined medtech company

by emma 3. November 2011 14:18

Medtech News

Medical device outsourcing company Vention Medical has acquired ATEK Medical Group, a leader in medical device assembly, packaging and injection moulding.

Dan Croteau, CEO of Vention Medical, said, “Our partnership with the ATEK Medical Group management team will allow Vention to provide an enhanced customer experience. Like Vention, ATEK Medical Group aspires to continually satisfy customers through intense focus on services that improve quality, innovation, and cost.”

The acquisition will incur a variety of combined capabilities and services, including product design and development, innovative component technologies, along with the manufacturing space of 175,000 square feet at its Costa Rica campus.

ATEK recently opened a second facility in Grand Rapids, Michigan, to support customer demands in the US.

Chris Oleksy, President of ATEK Medical, and Tom Houdeshell of ATEK Plastics, said that Vention’s experience and capabilities in design, components and assembly makes Vention “a very appealing partner for us”.

Vention Medical specialises in components and services used in interventional and minimally-invasive products, including medical balloons, advanced extrusions and heat shrink tubing, clean room injection moulding, assembly and packaging services.

Contract sales revenues continue to grow

by emma 5. October 2011 12:46

Pf industry news

Global pharmaceutical contract sales revenues will reach $5.24bn in 2015, a new report predicts.

The World Pharma Contract Sales Organisation (CSO) Market 2011-2021 found that revenues will continue to grow over the next decade as pharma companies look to cut costs.

Richard Lang, pharmaceutical industry analyst, says pharmaceutical companies are turning to CSOs for “new approaches to sales, targeting doctors and healthcare payers”.

The report by Visiongain found that supplying sales teams was currently the largest source of revenue for outsourcing companies in 2010, accounting for 80% of the market.

Pharma companies based in the US, UK and Japan will continue reduce sales forces, the report predicts, in coming years, providing an opportunity for contract sales companies and sales teams.

An increased emphasis on speciality drugs will also require new procedures and expertise for CSO sales teams, the report says, with e-detailing, tele-detailing and medical science liaison having a greater prominence over the next ten years.

“Face-to-face detailing of healthcare professionals is still the most common pharmaceutical sales technique in many markets,” said Mr Lang. “However, with increasingly busy schedules, more and more doctors are implementing 'no-see' policies for sales reps.

“The drive to cut rising healthcare costs will increase the influence of payers in future prescribing decisions.”

The demand for contract sales services is also expected to continue to grow in emerging markets such as China and India, according to the report’s predictions, with companies seeking to enter or expand their sales field-force presence in these regions and rely increasingly on the local knowledge and expertise CSOs offer.

TextBox

Tag cloud

Calendar

<<  June 2013  >>
MoTuWeThFrSaSu
272829303112
3456789
10111213141516
17181920212223
24252627282930
1234567

View posts in large calendar